Bristol-Myers Squibb Company
Bristol-Myers Squibb Company
Your view on BMY
Overview
What the company does, where it operates, and who runs it.
About Bristol-Myers Squibb Company
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Christopher S. Boerner
- Headquarters
- 430 East 29th Street, Princeton, NY, US
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Christopher S. Boerner
- Headquarters
- 430 East 29th Street, Princeton, NY, US
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases.
The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma.
In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML.
It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Bristol-Myers Squibb Company, and the rating behind it. BMY last traded at $63.64, 14.0× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Bristol-Myers Squibb Company. Starting points for Bristol-Myers Squibb Company: P/E 14.0, EPS $4.55, beta 0.23 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Bristol-Myers Squibb Company. Bristol-Myers Squibb Company paid $2.51 per share over the last year — a 3.9% yield at the current $63.64 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Bristol-Myers Squibb Company. Trailing twelve-month EPS for Bristol-Myers Squibb Company stands at $4.55. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Bristol-Myers Squibb Company. Bristol-Myers Squibb Company has reported as a listed company since 1972. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Bristol-Myers Squibb Company valued side by side against its closest peers. Bristol-Myers Squibb Company is measured against Drug Manufacturers - General peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Bristol-Myers Squibb Company, and how their positions are changing. At a $130.00B market value, institutional positions materially move Bristol-Myers Squibb Company's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Bristol-Myers Squibb Company executives and directors. Shares of Bristol-Myers Squibb Company have traded between $42.52 and $63.33 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is a $130.00B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Bristol-Myers Squibb Company. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Bristol-Myers Squibb Company. Coverage tracks Bristol-Myers Squibb Company within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.